QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-fennec-pharmaceuticals-maintains-13-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains ...

 craig-hallum-maintains-buy-on-fennec-pharmaceuticals-raises-price-target-to-14

Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price targ...

 fennec-pharmaceuticals-q2-eps-011-misses-004-estimate-sales-965m-beat-952m-estimate

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate...

 hc-wainwright--co-reiterates-buy-on-fennec-pharmaceuticals-maintains-13-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains ...

 craig-hallum-maintains-buy-on-fennec-pharmaceuticals-raises-price-target-to-13

Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price targ...

 fennec-pharmaceuticals-q1-eps-004-beats-009-estimate-sales-875m-beat-818m-estimate

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate o...

 hc-wainwright--co-reiterates-buy-on-fennec-pharmaceuticals-maintains-13-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains ...

 nasdaq-sp-500-hit-6-month-lows-as-recession-fears-grow-whats-driving-markets-monday

Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq ...

 fennec-pharmaceuticals-q4-2024-gaap-eps-006-up-from-010-yoy-sales-792m-down-from-973m-yoy

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.06) per share. This is a 40 percent increase over losses ...

Core News & Articles

Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that Norgine Pharmaceut...

 fennec-pharmaceuticals-announced-the-early-repayment-of-13m-of-its-approximately-32m-outstanding-convertible-debt-facility-with-petrichor-healthcare-capital-management

Pro forma for repayment, the convertible debt facility with Petrichor will be approximately $19 million and maintain a maturity...

 hc-wainwright--co-reiterates-buy-on-fennec-pharmaceuticals-maintains-13-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains ...

 fennec-pharmaceuticals-q3-eps-021-misses-010-estimate-sales-697m-miss-882m-estimate

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate...

 hc-wainwright--co-maintains-buy-on-fennec-pharmaceuticals-lowers-price-target-to-13

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and lowers the ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION